Tryngolza now publicly reimbursed through RAMQ in Quebec
TRYNGOLZA is listed on the Régie de l’assurance maladie du Québec (RAMQ) List of Medications for eligible patients, in accordance with the applicable coverage criteria.
Closing the gap between breakthrough medicines and the patients who need these the most.
Through disciplined execution, strategic partnerships and deep expertise in rare and specialty medicines, we identify and bring cutting edge therapies developed globally to Canada so ensuring patients have rapid access to these innovative treatments.
Interview with Paul Lévesque, President of CELYSTRA Pharma, on the show Zone économie | ICI RDI
Watch an interview our President, Paul Lévesque, gave to Gérald Filion on his show Zone économie on ICI RDI on June 15.
Tryngolza now available in Canada.
Tryngolza is Health Canada- approved.
Latest News
-
Québec Becomes First Province to Cover TRYNGOLZA® (olezarsen) for Familial Chylomicronemia Syndrome
Coverage under Québec’s public drug plan provides access to the first therapy approved by Health Canada for this rare genetic disease.
-
Interview with Paul Lévesque on ICI RDI’s “Zone Économie”
Watch an interview our president, Paul Lévesque, gave to Gérald Filion on his show Zone Économie on ICI RDI.
Health Canada-approved
In rare and specialty diseases, unmet need isn’t just a gap in treatment — it’s families waiting, patients hoping, and time we cannot afford to lose. We built this company to ensure that innovative science doesn’t sit on a shelf, but reaches the people whose lives depend on it.
— Paul Lévesque, President, Chief Executive Officer & Co-founder
Our Focus
Bringing much needed innovative treatments to Canadian patients.
Leadership Team
Decades of Expertise. One Shared Mission.
CELYSTRA was founded by Paul Lévesque, John Leasure and Philippe Dubuc, three executives with extensive pharmaceutical industry experience, particularly in drug development, commercialization and financing.
Partnerships
Accelerating access to patients.
We bring the know-how to effectively navigate partnered medicines through regulatory approval and Canada’s complex market access environment with a focus on commercial availability.